# Strategic Feedback — GPT-5.4 (R1)

**Role:** Journal editor (AER perspective)
**Model:** openai/gpt-5.4
**Timestamp:** 2026-03-25T13:28:11.533134
**Route:** OpenRouter + LaTeX
**Tokens:** 10503 in / 3509 out
**Response SHA256:** aea023203e53d2ad

---

## 1. THE ELEVATOR PITCH

This paper asks whether legalizing Medical Aid in Dying (MAID) changes end-of-life medical care beyond the tiny number of patients who actually use it. Using staggered state adoption, it argues that MAID does **not** measurably shift Medicare spending away from hospitals and toward hospice, suggesting that the law’s broader “exit option” spillovers are limited, at least in aggregate spending data.

A busy economist should care because the paper is trying to answer a larger question than “what happened to spending in these seven states?”: when a socially salient legal option expands choice for a small group, does it also change norms, conversations, and treatment patterns for everyone nearby?

**Does the paper articulate this clearly in the first two paragraphs?**  
Not quite. The current opening is competent, but too quickly locked into a narrow Medicare-spending frame. It leads with end-of-life costs, which makes the paper sound like a fiscal accounting exercise. The more interesting pitch is about whether a morally and politically controversial law has system-wide behavioral spillovers that far exceed direct use. That is the hook.

**What the first two paragraphs should say instead:**

> Medical Aid in Dying is one of the most controversial health policies in the United States. Although only a very small share of terminally ill patients ever use MAID, proponents and critics alike argue that legalization changes end-of-life care more broadly: it may alter physician-patient conversations, normalize advance care planning, and shift treatment away from aggressive hospital care toward hospice and palliation.  
>   
> This paper asks whether those broader spillovers actually occur. Using the staggered adoption of MAID laws across U.S. states, I test whether legalization changes the composition of Medicare end-of-life-sensitive spending. I find no detectable shift toward hospice or away from inpatient care, implying that MAID’s policy relevance is likely ethical and autonomy-based rather than fiscal.

That is the paper’s real pitch. Right now the introduction only partially delivers it.

---

## 2. CONTRIBUTION CLARITY

**One-sentence contribution:**  
The paper provides evidence that MAID legalization does not generate detectable spillovers in Medicare spending composition, contrary to the common claim that simply creating the option changes end-of-life care for non-users.

### Is this contribution clearly differentiated from the closest papers?
Only somewhat. The paper distinguishes itself from:
1. descriptive MAID utilization reports,
2. speculative cost projections,
3. broader end-of-life spending papers,
4. methodological staggered-DiD work.

But it does not yet sharply differentiate itself from the most relevant substantive question: **does MAID change care patterns beyond direct users?** That question is the contribution. The current draft sometimes muddies that with “first causal evaluation” language and a side contribution on TWFE bias. “First causal evaluation” is rarely a compelling top-journal claim by itself.

### World question or literature-gap question?
The paper is at its strongest when framed as a **world question**:
- Does legalizing a rare but salient exit option reshape how the medical system treats dying patients?

It weakens itself when framed as:
- There is no causal paper on MAID spending using modern staggered DiD.

The latter is a methods-and-gap claim. The former is an economics-of-policy-and-behavior claim.

### Could a smart economist explain what is new?
Right now, maybe, but with too much hesitation. They might say:
> “It’s a DiD paper on MAID laws and Medicare spending that finds no effect.”

That is not enough. You want:
> “It tests the central spillover claim in the MAID debate—that legal access changes end-of-life care for many more people than the few who use it—and finds basically no aggregate spending response.”

That version is much stronger.

### What would make the contribution bigger?
Very specifically, the paper would become much bigger if it moved from **aggregate Medicare category spending** to outcomes closer to the actual margin of interest:
- hospice enrollment among decedents,
- ICU use in the last 30 days of life,
- hospital death vs home death,
- late-life chemotherapy or intensive treatment,
- advance directive completion,
- palliative care consultation,
- length of hospice stay,
- family-reported care concordance.

As written, the paper tests the spillover hypothesis using a fairly distant proxy. That creates a scope problem: even if the estimate is clean, the outcome is not the closest manifestation of the behavior being theorized.

A second way to make it bigger would be heterogeneity with real substance:
- by baseline hospice intensity,
- by religiosity / political ideology,
- by urban physician supply,
- by cancer-heavy vs non-cancer end-of-life populations,
- by states with stronger palliative-care infrastructure.

That could turn “nothing on average” into “spillovers exist only where end-of-life care systems can actually translate the law into practice.”

---

## 3. LITERATURE POSITIONING

### Closest neighbors
The paper sits near several conversations:

1. **End-of-life care and spending**
   - Kelley et al. on hospice and end-of-life spending
   - Riley and Lubitz-style Medicare end-of-life spending concentration work
   - Dartmouth / geographic variation work on treatment intensity near death

2. **MAID / physician-assisted dying**
   - Oregon and Washington descriptive reports
   - Emanuel-style ethics/cost commentary and cost projections
   - Health services papers on hospice use and physician behavior in MAID states

3. **Policy spillovers / option value / salience**
   - This is where the paper wants to go conceptually, though the Finkelstein “option value” analogy currently feels imported rather than earned

4. **Modern staggered adoption DiD**
   - Goodman-Bacon
   - Callaway and Sant’Anna
   - Sun and Abraham
   - de Chaisemartin and D’Haultfoeuille

### How should it position itself relative to those neighbors?
It should **build on** the end-of-life care and MAID literatures, and use the DiD literature only as a tool. Right now the paper overinvests in making the methodology itself feel like a contribution. For AER, that is almost certainly the wrong strategic choice unless the method delivers a genuinely surprising substantive reversal on the core outcome. Here, it mostly produces a sign reversal on ER visits, which is not the heart of the paper.

So:
- build on the end-of-life care literature,
- test a central claim in the MAID debate,
- use modern DiD as necessary hygiene, not as the headline.

### Is the paper positioned too narrowly or too broadly?
Paradoxically, both.

- **Too narrowly** in outcome choice: Medicare FFS spending categories are a narrow empirical object.
- **Too broadly** in rhetorical ambition: it sometimes claims to adjudicate the “exit option hypothesis” writ large.

At present, the paper can more safely claim:
> MAID legalization did not measurably alter Medicare FFS spending composition in the observed post-adoption years.

That is narrower than the grand theory. To claim more, it needs closer outcomes.

### What literature does it seem unaware of?
It should speak more directly to:
- **health economics of end-of-life treatment intensity**
- **palliative care adoption and hospice substitution**
- **behavioral responses to legally available options with very low take-up**
- perhaps even **law and economics of expressive policy**, if it wants to lean into symbolic effects

The current “option value in health policy” framing feels a bit forced and underdeveloped. If the paper wants that frame, it needs to do more conceptual work. Otherwise it should stay grounded in end-of-life care.

### Is it having the right conversation?
Almost. The best conversation is not “modern DiD applied to MAID.” It is:
> When policymakers create a rare but symbolically powerful medical option, do they change treatment norms system-wide?

That is a broader and more interesting conversation, and it connects health, law, and political economy.

---

## 4. NARRATIVE ARC

### Setup
MAID is expanding across states. Direct use is rare, but commentators claim legalization changes the broader culture and practice of dying—more planning, more palliation, less aggressive hospital care.

### Tension
That broad-spillover claim is central to the public debate, yet there is little credible evidence on whether MAID actually changes care patterns at scale.

### Resolution
In Medicare FFS spending data, legalization does not produce detectable shifts toward hospice or away from inpatient care.

### Implications
The case for MAID should not rest on expected budget savings or broad system transformation. If MAID matters, it likely matters through autonomy and ethics, not through aggregate fiscal effects.

### Does the paper have a clear narrative arc?
Mostly yes, but it is diluted by two problems:

1. **The paper keeps drifting into a methods paper.**  
   The TWFE-vs-CS discussion is fine, but it hijacks the storyline. The core story is about MAID spillovers, not forbidden comparisons.

2. **The evidence feels somewhat more modest than the rhetoric.**  
   The narrative says it is testing whether MAID changes end-of-life care norms. But the actual evidence is county-level Medicare FFS spending categories. That is related, but not identical. So the paper risks feeling like a collection of sensible estimates wrapped in a story slightly bigger than the outcomes can bear.

**What story should it be telling?**  
Not “MAID doesn’t matter.”  
Rather:
> A central empirical claim in the MAID debate is that legal access changes care patterns for many more patients than direct users. In broad Medicare spending data, I do not find evidence of such spillovers.

That is cleaner, more defensible, and more persuasive.

---

## 5. THE “SO WHAT?” TEST

### What fact would I lead with at a dinner party?
> Despite all the claims that legalizing MAID would shift dying patients out of hospitals and into hospice, there is basically no detectable effect on Medicare spending patterns.

That is the fact.

### Would people lean in?
Some would—especially health economists, public finance people, and anyone interested in law-and-economics of controversial medical policies. But many would ask an immediate follow-up:
> “Okay, but are spending aggregates the right place to look? Maybe the real effects are on place of death, timing, patient autonomy, or care quality.”

That follow-up question is exactly the paper’s strategic vulnerability.

### Is the null interesting?
Yes, potentially. But the paper must make the case more sharply that the null is informative because:
- direct use is tiny,
- the spillover claim is central to public and policy rhetoric,
- large system-wide effects were genuinely plausible ex ante,
- the estimates rule out changes of economically meaningful size.

The paper already gestures in this direction. It should lean harder into:
> This is not a failed attempt to find an effect; it is a direct test of a prominent claim, and the null is substantively meaningful.

That said, a null in broad spending categories is less exciting than a null in more behaviorally precise outcomes. The null is interesting, but not maximally so.

---

## 6. STRUCTURAL SUGGESTIONS

### What would make it read better?

**1. Shorten the methodology signaling in the introduction.**  
The current introduction devotes too much premium real estate to the TWFE sign flip. That belongs later, unless ER visits are somehow the conceptual center of the paper—which they are not.

**2. Front-load the substantive result.**  
The null on hospice/inpatient/total spending should appear before the methodological aside. A reader should know by page 2 what the paper found and why it matters.

**3. Demote the methodological contribution.**  
Present modern staggered DiD as the correct implementation, not as one of the three main contributions. For this paper, that reads as overcompensation.

**4. Tighten the literature review.**  
The current tripartite contribution paragraph is serviceable but generic. Replace “contributes to three literatures” with a more integrated paragraph centered on the substantive debate.

**5. Move some inferential detail out of the main text.**  
Wild cluster bootstrap specifics, minimum detectable effect calculations, and some of the methodological exposition can be streamlined or pushed back. The paper currently feels eager to prove seriousness before it earns interest.

**6. Elevate any more direct outcome if available.**  
If hospice utilization is the closest behavioral outcome in the current data, it should be treated as a more central result, not a side note. Right now it is buried.

**7. Rethink the conclusion.**  
The conclusion mostly summarizes. It should instead do one of two things:
- either narrow the claim and state exactly what the paper can and cannot rule out,
- or broaden the implications by linking to expressive policy, symbolic legislation, and low-take-up options more generally.

At present it does neither fully.

---

## 7. WHAT WOULD MAKE THIS AN AER PAPER?

Bluntly: in current form, this feels more like a solid field-journal paper than an AER paper.

### What is the gap?

**Primarily a scope/ambition problem, with some framing issues.**

- **Framing problem:** The paper has a better question than it currently sells.
- **Scope problem:** The outcomes are too aggregate and too far from the underlying behavioral margin to support the biggest version of the story.
- **Ambition problem:** The paper is careful and competent, but safe. It settles for category spending when the real question is about how people die and how doctors treat dying patients.
- **Novelty problem:** The substantive claim is interesting, but the evidence package is not yet rich enough to feel field-defining.

### What would excite the top 10 people in this field?
A paper that convincingly answers:
> Does MAID legalization change end-of-life treatment intensity, hospice use, place of death, and care planning for the much larger population of terminal patients who never use MAID?

That would be a big paper. This manuscript is currently a narrower version:
> Does MAID legalization change county-level Medicare FFS spending categories?

That is respectable, but not yet AER-level unless attached to much sharper outcomes, broader implications, or a more surprising pattern of heterogeneity.

### Single most impactful advice
**If the author can change only one thing:**  
Replace or substantially supplement aggregate Medicare spending outcomes with outcomes closer to actual end-of-life decision-making behavior; if that is impossible, then narrow the claim and sell the paper as evidence against fiscal-spillover arguments rather than as a general test of the exit-option hypothesis.

---

### Strategic Assessment

- **Current framing quality:** Adequate
- **Contribution clarity:** Somewhat fuzzy
- **Literature positioning:** Could be stronger
- **Narrative arc:** Serviceable
- **AER distance:** Medium
- **Single biggest improvement:** Use outcomes closer to end-of-life treatment behavior—or sharply narrow the claim to “no detectable Medicare spending spillovers” rather than “no exit-option effect.”